Related Experiment Video
Updated: Aug 29, 2026

Isolated Pancreatic Islet Treatment and Apoptosis Measurement
Published on: May 2, 2025
GLP-1 inhibition of pancreatic islet cell apoptosis
Irina A Urusova1, Loredana Farilla, Hongxiang Hui
1Division of Endocrinology and Metabolism, Cedars-Sinai Medical Center, 8723 Alden Drive, Suite 290, Los Angeles, CA 90046, USA.
Abstract:
Apoptosis plays an important role in the normal physiology of the pancreas, the pathogenesis of diabetes mellitus (DM) and the success rate of islet transplantation. Glucagon-like peptide-1 (GLP-1), an incretin hormone with multiple effects on glucose metabolism and pancreatic gene expression, has recently been found to have antiapoptotic properties. This new property of GLP-1 has clinical relevance for the treatment of patients with overt DM, possible prevention of DM during the stage of impaired glucose tolerance and improvement in the outcome of islet transplantation. The pleiotropic effects of GLP-1 have fostered considerable interest in evaluating the efficacy of GLP-1, and might lead in the near future to its use in the prevention and/or treatment of DM.
Insights
Glucagon-like peptide-1 (GLP-1) exhibits antiapoptotic properties, crucial for pancreatic health and diabetes mellitus (DM) treatment. This finding holds promise for preventing DM and enhancing islet transplantation success.
Area of Science:
- Endocrinology
- Cell Biology
- Metabolic Diseases
Background:
- Apoptosis is integral to pancreatic function, diabetes mellitus (DM) development, and islet transplantation outcomes.
- Glucagon-like peptide-1 (GLP-1), a key incretin hormone, influences glucose metabolism and pancreatic gene expression.
- Emerging research highlights GLP-1's significant antiapoptotic effects.
Purpose of the Study:
- To investigate the antiapoptotic role of Glucagon-like peptide-1 (GLP-1).
- To explore the clinical implications of GLP-1's antiapoptotic properties in diabetes mellitus and islet transplantation.
- To assess the potential of GLP-1 in preventing and treating diabetes mellitus.
Main Methods:
- Review of existing literature on GLP-1, apoptosis, and diabetes.
- Analysis of GLP-1's mechanisms of action on pancreatic cells.
- Evaluation of clinical relevance for DM treatment and islet transplantation.
Main Results:
- Glucagon-like peptide-1 (GLP-1) demonstrates potent antiapoptotic effects.
- These properties are relevant for managing overt diabetes mellitus.
- GLP-1 may aid in preventing DM in impaired glucose tolerance stages and improve islet transplant success.
Conclusions:
- The antiapoptotic function of GLP-1 presents a novel therapeutic avenue.
- GLP-1's pleiotropic effects warrant further investigation for DM prevention and treatment.
- GLP-1 holds significant potential for improving outcomes in metabolic and transplant medicine.
Related Concept Videos
Dipeptidyl Peptidase 4 Inhibitors
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
Insulin and C-peptide are co-secreted in...
Hormones Regulating Blood Glucose
In addition to accelerating glucose uptake and utilization, insulin has...
Oral Hypoglycemic Agents: Glinides
Cell Specific Gene Expression

